Orelabrutinib
- Generic Name
- Orelabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O3
- CAS Number
- 1655504-04-3
- Unique Ingredient Identifier
- WJA5UO9E10
- Background
Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
- Indication
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
- Conditions
- PCNSLRefractory and Relapsed Primary CNS LymphomaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 29
- Registration Number
- NCT05021770
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 40
- Registration Number
- NCT05020288
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Puyang Oilfield General Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT05014100
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
- Conditions
- Follicular LymphomaRelapsed and Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 32
- Registration Number
- NCT04989621
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,, Guangzhou, Guangdong, China
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,, Guangzhou, Guangdong, China
Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma
- Conditions
- Primary Central Nervous System Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 48
- Registration Number
- NCT04961515
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04899427
- Locations
- 🇨🇳
Wei Zhang, Beijing, Beijing, China
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Other: placebo
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT04711148
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China
🇺🇸Neurology Associates, P.C., Lincoln, Nebraska, United States
🇺🇦CNE Regional Clinical Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, Ukraine
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT04578613
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia Refractory
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT04440059
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Union Hospital affiliated to Fujian Medical University, Fuzhou, Fujian, China
A Study of ICP-022 in Patients With R/R DLBCL
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT04438005
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Harbin Medical University, Haerbin, Heilongjiang, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.